Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Immix Biopharma, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 23 | 22 | −1 |
| Shares | 2.87M | 2.92M | +47.5K (+1.7%) |
| Value | $6.32M | $4.90M | −$1.41M (−22.4%) |
New holders (3)
Institutions that held Immix Biopharma, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 55,262 | $92.8K | 0.00% |
| XTX Topco Ltd | 12,833 | $21.6K | 0.00% |
| Northwestern Mutual Wealth Management Co | 80 | $134 | 0.00% |
Sold out (4)
Institutions that held Immix Biopharma, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Jane Street Group, LLC | 17,523 | $38.6K |
| Royal Bank of Canada | 2,000 | $4.00K |
| Tortoise Investment Management, LLC | 1,300 | $2.86K |
| Simplex Trading, LLC | 22 | $0 |